Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on July 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). 2025 net product sales rose to $634.2M from $528.3M, led by Galafold sales of $521.7M and Pombiliti plus Opfolda sales of $112.5M.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- 2025 net product sales rose to $634.2M from $528.3M, led by Galafold sales of $521.7M and Pombiliti plus Opfolda sales of $112.5M
- Operating income reached $32.8M, but $46.2M interest expense and $27.3M income tax expense drove a $27.1M net loss
- Operating cash flow turned positive at $33.1M versus negative $33.9M in 2024, supporting near-term funding flexibility
- Cash and marketable securities totaled $293.5M against $392.7M long-term debt at December 31, 2025
- Pending BioMarin merger would cash out shares at $14.50 each and end Amicus public listing upon completion
Item EX-99.2 · Exhibit EX-99.2
- Amicus acquisition closed April 27, 2026 for $5.324B, including $14.50 cash per share and assumed transaction-related obligations
- Financing adds $3.650B debt, including $2.800B term facilities and $850M 5.50% senior notes due 2034
- Pro forma debt reaches $4.132B, while cash and investments fall to $547M, materially increasing leverage and reducing liquidity
- Combined 2025 revenue would have been $3.855B, but acquisition accounting produces a $205.9M net loss and $1.07 diluted loss per share
- Preliminary valuation assigns $4.750B to acquired intangibles and $496.4M to goodwill, creating approximately $393.6M annual amortization before inventory step-up effects
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.